PDGFβ Receptor Blockade Inhibits Intimal Hyperplasia in the Baboon

Author:

Hart Charles E.1,Kraiss Larry W.1,Vergel Selina1,Gilbertson Debra1,Kenagy Richard1,Kirkman Thomas1,Crandall David L.1,Tickle Simon1,Finney Helene1,Yarranton Geoff1,Clowes Alexander W.1

Affiliation:

1. From ZymoGenetics, Seattle, Wash (C.E.H., D.G.); the Division of Vascular Surgery, University of Utah, Salt Lake City (L.W.K.); the Department of Surgery, University of Washington, Seattle (S.V., R.K., A.W.C.); BioDevelopment, Bellevue, Wash (T.K.); Wyeth-Ayerst Research, Princeton, NJ (D.L.C.); and Celltech Therapeutics, Slough, UK (S.Y., H.F., G.Y.).

Abstract

Background —We have evaluated the use of a mouse/human chimeric anti–platelet-derived growth factor-β receptor antibody in combination with heparin to inhibit intimal hyperplasia in the saphenous artery of the baboon after balloon angioplasty. Methods and Results —The study evaluated lesion development in sequential injuries made 28 days apart. Each animal received control treatment after the first injury and antibody/heparin therapy after the second injury to the contralateral artery. The antibody was administered by bolus intravenous injections (10 mg/kg) on study days 1, 4, 8, 15, and 22 and heparin coadministered by continuous intravenous infusion at a dose of 0.13 mg/kg per hour. Morphometric analysis of tissue sections showed a 53% decrease in intimal area after antibody/heparin treatment ( P =0.005), corresponding to a 40% decrease in the intima-to-media ratio ( P =0.005). Smooth muscle cell proliferation in the injured wall, measured at both 4 and 29 days after balloon injury, were similar in the control and antibody/heparin-treated animals. Conclusions —These data suggest that platelet-derived growth factor plays a key role in the development of intimal lesions at sites of acute vascular injury in the nonhuman primate.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Physiology (medical),Cardiology and Cardiovascular Medicine

Cited by 100 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3